Latest Breaking News On - Marketing authorisations - Page 5 : comparemela.com
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be s
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAINT-CLOUD, France, May 19, 2021 /PRNewswire/ Ethypharm announces today that it has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. This agreement confirms Ethypharm s commitment to patients whose daily life is altered by pain.
Migraine is one of the most common neurological conditions, affecting about 12% of the population in Europe. In the management of acute migraine attacks, many medicines are already available. However, patients may not be always satisfied with the efficacy of existing treatments and some may have concerns about their potential side effects. There is therefore a need to offer further alternatives to patients suffering from acute migraine attacks.
Summary of Product Characteristics and product literature for veterinary medicines
Guidance for the veterinary pharmaceutical industry on the production and submission of the Summary of Product Characteristics (SPCs) and product literature mock-ups.
From: Contents
Print this page
This guidance applies to applications for national and mutually recognised Marketing Authorisations (MAs) and Veterinary Homeopathic Remedies (VHRs). It does not apply to Centralised applications. VHRs do not have SPCs.
Product Literature Standard
Joint labelling with Ireland
Joint labelling is the term used for a single label/leaflet that has been agreed by the UK and Ireland for use on veterinary medicines marketed in their countries.